SCHEMBL25720505

SCHEMBL25720505

CN(C)C(=O)Cc1ccc(Cn2c(=O)[nH]c3ccccc32)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.63
HTT P42858 2/20 0.63
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
KMT2A Q03164 1/20 0.51
PARP1 P09874 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 2/20 0.45
RAB9A P51151 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PGR P06401 2/20 0.43
USP1 O94782 1/20 0.41
DAO P14920 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30336805 0.90 LMNA (0.53) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL23997192 0.90 LMNA (0.53) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL30336790 0.85 HTT (0.48) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL23997260 0.85 HTT (0.48) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL7222541 0.85 LMNA (0.63) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL25720727 0.84 DAO (0.47) LMNAHTTMEN1KMT2APARP1
SCHEMBL30336888 0.84 LMNA (0.69) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL23997320 0.84 LMNA (0.69) LMNAHTTMEN1CYP1A2KMT2A
SCHEMBL23997267 0.83 HDAC1 (0.47) LMNAHTTMEN1KMT2APARP1
SCHEMBL25720041 0.83 PARP1 (0.43) LMNAHTTMEN1KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183214-A1 IL4I1 INHIBITORS AND METHODS OF USE IL4I1, IL4, IL2 LMNA 4017/4885HTT 4501/4885MEN1 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.